Forfenimex

• CAT Number: I027695
• CAS Number: 71522-58-2
• Molecular Formula: C9H11NO4
• Molecular Weight: 197.19
• Purity: ≥95%
• Synonyms: Forfenimex; BF 121; BF121; BF-121.
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
• IUPAC Name: (+)-(S)-2-(alpha,3-Dihydroxy-p-tolyl)glycine
• InChI: InChI=1S/C9H11NO4/c10-8(9(13)14)5-1-2-6(4-11)7(12)3-5/h1-3,8,11-12H,4,10H2,(H,13,14)/t8-/m0/s1
• InChIKey: JRBXPUUAYKCCLQ-QMMMGPOBSA-N
• SMILES: N[C@@H](C1=CC=C(CO)C(O)=C1)C(O)=O

Forfenimex (Cat.No:I027695) is a chemical compound that belongs to the phenylalkylamine class. It acts as a selective norepinephrine-dopamine reuptake inhibitor (NDRI) and has stimulant properties. Forfenimex has been studied for its potential as a psychoactive substance, but it is not approved for medical or therapeutic use. 

Reference

1: Murphy KT, Wardak A, Beckett MA, Lopez CA, Mehta N, Kimchi E, Salloum RM, Jaskowiak NT, Posner MC, Ohno T, Kufe DW, Weichselbaum RR, Mauceri HJ. Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma. Cancer Chemother Pharmacol. 2005 Sep;56(3):317-21. Epub 2005 May 11. PubMed PMID: 15887016.
2: Tanaka M, Hori Y, Sakai F, Ueda H, Goto T, Okuhara M, Tsuda Y, Okada Y. WS1279, a novel lipopeptide isolated from Streptomyces willmorei. Biological activities. J Antibiot (Tokyo). 1993 Nov;46(11):1699-706. PubMed PMID: 8270492.
3: Koyama Y, Huang SP, Ikeda D, Hamada M, Kondo S, Takeuchi T. Orally absorbable D-forphenicinol-cephalosporins. J Antibiot (Tokyo). 1989 Jun;42(6):993-9. PubMed PMID: 2737957.
4: Ishihara K, Hayasaka K, Yamazaki N. Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan. J Invest Dermatol. 1989 May;92(5 Suppl):326S-328s. PubMed PMID: 2469742.
5: Chao WF, Kai M, Ohkura Y. High-performance liquid chromatographic determination of forphenicine in mouse serum and muscle by pre-column fluorescence derivatization using 1,2-diamino-4,5-ethylenedioxybenzene as fluorogenic reagent. J Chromatogr. 1988 Sep 9;430(2):361-7. PubMed PMID: 3235509.
6: Hoeprich PD, Merry JM. Comparative efficacy of forphenicinol, cyclosporine, and amphotericin B in experimental murine coccidioidomycosis. Diagn Microbiol Infect Dis. 1987 Apr;6(4):287-92. PubMed PMID: 3581735.
7: Ishibashi T, Takamoto M, Shinoda A, Kihara H, Nagano H, Kawakami K, Yamato Y, Nakanishi K, Yamamoto T, Otsu T, et al. [Clinical trial of forphenicinol for the lung infection with Mycobacterium avium, Mycobacterium intracellulare complex]. Jpn J Antibiot. 1987 Apr;40(4):711-26. Japanese. PubMed PMID: 3302344.
8: Naito K, Arakawa H, Watanabe Y, Okura A, Ishizuka M, Takeuchi T, Umezawa H. Protective effect of forphenicinol, a low molecular weight immunomodifier, against infection with Pseudomonas aeruginosa in mice and its mechanisms. J Antibiot (Tokyo). 1987 Apr;40(4):547-54. PubMed PMID: 3034847.
9: Okura A, Naito K, Iizuka H, Ishizuka M, Takeuchi T, Umezawa H. Effect of forphenicinol, a low molecular weight immunomodifier, on the growth of and the immune responses to murine lymphoma EL4. J Biol Response Mod. 1987 Feb;6(1):35-43. PubMed PMID: 3559627.
10: Okura A, Nakadaira M, Naito K, Arakawa H, Ishizuka M, Takeuchi T, Umezawa H. Effect of forphenicinol on the production of lipopolysaccharide-induced interferon and tumor necrosis factor and on the growth of Meth A fibrosarcoma in mice. J Biol Response Mod. 1987 Feb;6(1):28-34. PubMed PMID: 2435854.
11: Ohhara N, Okamura S, Otsuka T, Harada M, Niho Y. Stimulatory effect of forphenicinol on normal human bone marrow granulocyte-macrophage progenitor cells mediated by T-lymphocytes. Biomed Pharmacother. 1987;41(8):425-8. PubMed PMID: 3502533.
12: Uchiyama N, Takano T, Saito S, Morikawa H, Ohtawa M. Quantitative determination of forphenicinol and its metabolites in human serum and urine by gas chromatography/mass spectrometry with selected ion monitoring. Chem Pharm Bull (Tokyo). 1986 Aug;34(8):3290-7. PubMed PMID: 3791500.
13: Kai M, Tamura K, Ohno M, Ohkura Y. Simple determination of forphenicinol in human plasma and erythrocytes by HPLC with native fluorescence detection. Biomed Chromatogr. 1986 Aug;1(4):143-6. PubMed PMID: 3506826.
14: Miura K, Sawa T, Takeuchi T, Umezawa H. Effects of enzyme inhibitors in inhibiting the growth and inducing the differentiation of human promyelocytic leukemia cells, HL-60. J Antibiot (Tokyo). 1986 May;39(5):734-5. PubMed PMID: 3460977.
15: Okura A, Sawazaki Y, Naito K, Ishizuka M, Takeuchi T, Umezawa H. Antitumor effect of forphenicinol, a low molecular weight immunomodifier, in combination with surgery on Meth A fibrosarcoma, Lewis lung carcinoma, and adenocarcinoma 755. J Antibiot (Tokyo). 1986 Apr;39(4):564-8. PubMed PMID: 3710915.
16: Okura A, Arakawa H, Yoshinari T, Naito K, Ishizuka M, Takeuchi T, Umezawa H. Effect of forphenicinol on the production of Ia-positive macrophages in mice with or without L1210 leukemia and on the growth of L1210 in immunized mice. J Antibiot (Tokyo). 1986 Apr;39(4):575-80. PubMed PMID: 3458691.
17: Okura A, Nakadaira M, Naito K, Ishizuka M, Takeuchi T, Umezawa H. Effect of forphenicinol on gamma-interferon production in mice sensitized with BCG. J Antibiot (Tokyo). 1986 Apr;39(4):569-74. PubMed PMID: 3011721.
18: Nitta K, Tanaka T. [Enhancement of immune response by an antitumor agent, cyclophosphamide]. Gan To Kagaku Ryoho. 1986 Mar;13(3 Pt 2):706-13. Japanese. PubMed PMID: 2938546.
19: Yoshimura K, Chonabayashi N, Nakatani T, Nakamori Y, Nakata K, Tanimoto H. [Clinical and immunological studies on forphenicinol, a low molecular weight immunomodulator, in chronic respiratory infections]. Kansenshogaku Zasshi. 1985 Oct;59(10):996-1004. Japanese. PubMed PMID: 3936891.
20: Kumano N, Nakai Y, Ishikawa T, Koinumaru S, Suzuki S, Oizumi K, Konno K. Changes in the immunological parameters after a single dose of forphenicinol, a new small molecular immunomodifier. Tohoku J Exp Med. 1985 Aug;146(4):419-27. PubMed PMID: 4071537.